Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Average Rating of “Hold” from Analysts

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have been given a consensus rating of “Hold” by the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $5.5125.

Several brokerages have recently commented on CHRS. Oppenheimer started coverage on Coherus Oncology in a research report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 target price for the company. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Coherus Oncology Trading Down 4.7%

Coherus Oncology stock opened at $1.63 on Monday. The company has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.49. Coherus Oncology has a 52 week low of $0.71 and a 52 week high of $2.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.23 and a current ratio of 1.24. The firm has a market capitalization of $243.64 million, a price-to-earnings ratio of 1.23 and a beta of 0.99.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CHRS. Invesco Ltd. raised its holdings in shares of Coherus Oncology by 45.6% during the 4th quarter. Invesco Ltd. now owns 380,033 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 119,041 shares in the last quarter. XTX Topco Ltd increased its position in Coherus Oncology by 71.6% during the fourth quarter. XTX Topco Ltd now owns 166,797 shares of the biotechnology company’s stock worth $237,000 after buying an additional 69,621 shares during the last quarter. Millennium Management LLC bought a new position in Coherus Oncology during the fourth quarter valued at about $938,000. Bridgeway Capital Management LLC lifted its position in shares of Coherus Oncology by 72.9% in the fourth quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock worth $626,000 after buying an additional 186,000 shares during the last quarter. Finally, Blair William & Co. IL acquired a new stake in shares of Coherus Oncology in the fourth quarter worth about $27,000. 72.82% of the stock is owned by hedge funds and other institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.